MedDataX Logo

Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise

NCT ID: NCT00946829

Last Updated: 2019-11-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

18299 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the observational study is to ascertain the degree of blood pressure control in the early-morning hours after 8 weeks of treatment with Telmisartan/Telmisartan+Hydrochlorothiazide and during 44 weeks of follow-up, in patients with hypertension using home blood pressure measurements.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension

NCT02242383

Hypertension
COMPLETED

Micardis® in Patients With Essential Hypertension

NCT02187705

Hypertension
COMPLETED

Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

NCT00879411

Hypertension
COMPLETED

Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk Hypertensives

NCT00539487

Hypertension Obesity
COMPLETED

Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension

NCT00257491

Hypertension
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

telmisartan

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with mild to moderate essential hypertension and whose medical condition make them eligible for treatment with Telmisartan/Telmisartan+HCTZ

Exclusion Criteria

* Pre-menopausal women who had had no birth control, who are pregnant or nursing
* Patients with advanced hepatic impairment, advanced renal impairment or both
* Patients with functional class III or IV (NYHA) congestive heart failure (CHF), unstable angina, acute myocardial infarction, heart surgery or stroke within the previous six months
* Patients with any valvular disease with hemodynamic repercussion
* Patients receiving chronic administration of oral anticoagulants or digoxin
* Patients with known hypersensitivity to any component in the formulation of Micardis / MicardisPlus
* Patients with previous history of angioedema associated with ACE inhibitors
* Patients with severe, uncontrolled hypertension or any form of secondary hypertension
* Patients with any other clinical conditions which, in the opinion of the investigator, would not allow for the safe completion of the protocol
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site

Boehringer Ingelheim Investigational Site, , Belgium

Site Status

Boehringer Ingelheim Investigational Site

Boehringer Ingelheim Investigational Site, , Canada

Site Status

Boehringer Ingelheim Investigational Site

Boehringer Ingelheim Investigational Site, , Colombia

Site Status

Boehringer Ingelheim Investigational Site

Boehringer Ingelheim Investigational Site, , Czechia

Site Status

Boehringer Ingelheim Investigational Site

Boehringer Ingelheim Investigational Site, , Ecuador

Site Status

Boehringer Ingelheim Investigational Site

Boehringer Ingelheim Investigational Site, , Indonesia

Site Status

Boehringer Ingelheim Investigational Site

Boehringer Ingelheim Investigational Site, , Jordan

Site Status

Boehringer Ingelheim Investigational Site

Boehringer Ingelheim Investigational Site, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site

Boehringer Ingelheim Investigational Site, , Mexico

Site Status

Boehringer Ingelheim Investigational Site

Boehringer Ingelheim Investigational Site, , Turkey (Türkiye)

Site Status

Boehringer Ingelheim Investigational Site

Boehringer Ingelheim Investigational Site, , Venezuela

Site Status

Boehringer Ingelheim Investigational Site

Boehringer Ingelheim Investigational Site, , Yemen

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Canada Colombia Czechia Ecuador Indonesia Jordan Lebanon Mexico Turkey (Türkiye) Venezuela Yemen

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.425

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
NCT02177422 COMPLETED PHASE3
A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)
NCT02242396 COMPLETED
Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients
NCT01108809 COMPLETED
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension
NCT02242838 COMPLETED
An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension
NCT00904215 COMPLETED
Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension
NCT02242370 COMPLETED PHASE4
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
NCT00904371 COMPLETED
Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters
NCT00615108 COMPLETED
Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension
NCT02183701 COMPLETED PHASE3
PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
NCT00274599 COMPLETED PHASE4
Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5
NCT00239369 COMPLETED PHASE3
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
NCT00926289 COMPLETED PHASE4
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
NCT00326768 COMPLETED PHASE3
Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients
NCT02172586 COMPLETED PHASE4
Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension
NCT02269176 COMPLETED PHASE3
Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension
NCT02176499 COMPLETED PHASE3
Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension
NCT02177487 COMPLETED PHASE3
SMOOTH - Blood Pressure Control in Diabetic/Obese Patients
NCT00239538 COMPLETED PHASE4
Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients
NCT00267943 COMPLETED PHASE3
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
NCT00281593 COMPLETED PHASE3
Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension
NCT02242812 TERMINATED PHASE4
Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension
NCT02177409 COMPLETED PHASE3
Survey to Assess Why People Are Not Responding to Treatment in Hypertension
NCT01071681 COMPLETED
Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
NCT00281580 COMPLETED PHASE3
Clinical Efficacy of Telmisartan in Reducing Cardiac Remodeling Among Obese Patients With Hypertension
NCT03956823 UNKNOWN NA